Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL6806396 | 0.99 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL1848404 | 0.95 | PPARG (0.52) | PPARGPPARA | |
| SCHEMBL1847323 | 0.95 | PPARG (0.51) | PPARGPPARA | |
| SCHEMBL2177889 | 0.88 | PPARG (0.51) | PPARGPPARA | |
| SCHEMBL9803887 | 0.85 | PPARG (0.42) | PPARGPPARA | |
| SCHEMBL1845921 | 0.85 | PPARG (0.41) | PPARGPPARA | |
| SCHEMBL9206600 | 0.85 | PPARG (0.55) | PPARGPPARA | |
| SCHEMBL1073733 | 0.82 | PPARG (0.58) | PPARGPPARA | |
| Brl-48482 SCHEMBL1850299 | 0.82 | PPARG (0.68) | PPARGPPARA | |
| SCHEMBL1847381 | 0.82 | PPARG (0.42) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | BEECHAM GROUP P.L.C. | 2003-08-07 | — | — | US | claimed |
| EP-1306086-A2 | Use of thiazolidinediones for the treatment of atherosclerosis and eating disorders | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | claimed |
| US-20020049240-A1 | NOVEL COMPOUNDS | BEECHAM GROUP P.1.C. | 2002-04-25 | — | — | US | claimed |
| EP-0842925-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1998-05-20 | — | — | EP | claimed |
| EP-0695183-A1 | USE OF THIAZOLIDINEDIONES FOR THE TREATMENT OF ATHEROSCLEROSIS AND EATING DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1996-02-07 | — | — | EP | claimed |
| WO-1994025026-A1 | USE OF THIAZOLIDINEDIONES FOR THE TREATMENT OF ATHEROSCLEROSIS AND EATING DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-10 | — | — | WO | claimed |
| US-5232925-A | Treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | claimed |
| US-5002953-A | Substituted Thiazolidinedione Derivatives | BEECHAM GROUP P.L.C. (GB) | 1991-03-26 | — | — | US | claimed |
| EP-0306228-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1989-03-08 | — | — | EP | claimed |
| US-20210095345-A1 | METHOD OF IDENTIFYING DISEASE RISK FACTORS | ZINFANDEL PHARMACEUTICALS INC (US) | 2021-04-01 | — | — | US | disclosed |
| US-10865449-B2 | Method of identifying disease risk factors | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-2789695-B1 | Anti-Alzheimer's disease treatment of subjects identified by detecting the presence of a genetic variant in the TOMM40 gene at rs 10524523 | ZINFANDEL PHARMACEUTICALS INC (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180363060-A1 | METHOD OF IDENTIFYING DISEASE RISK FACTORS | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2018-12-20 | — | — | US | disclosed |
| US-20150073022-A1 | DISEASE RISK FACTORS AND METHODS OF USE | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| EP-2324126-A2 | METHOD OF IDENTIFYING DISEASE RISK FACTORS | Zinfandel Pharmaceuticals, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010019550-A2 | METHOD OF IDENTIFYING DISEASE RISK FACTORS | SHIRAZ PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-5589492-A | Heterocyclic compounds and their use in the treatment of Type-II diabetes | SMITHKLINE BEECHAM PLC (GB) | 1996-12-31 | — | — | US | disclosed |
| EP-0419035-B1 | Thiazolidine dione derivatives | BEECHAM GROUP PLC (GB) | 1995-02-15 | — | — | EP | disclosed |
| EP-0635007-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF TYPE II-DIABETES | SMITHKLINE BEECHAM PLC (GB) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993021166-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF TYPE II-DIABETES | SMITHKLINE BEECHAM PLC (GB) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | TYK2, FABP3, FABP4 | PPARG 16/4885PPARA 20/4885 |
| US-20020049240-A1 | NOVEL COMPOUNDS | GRK1, GRK3, GRK7 | PPARG 715/4885PPARA 2154/4885 |
| US-20150073022-A1 | DISEASE RISK FACTORS AND METHODS OF USE | TSG101, TOMM40, TOMM70 | PPARG 1229/4885PPARA 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.